What is the clinical effectiveness, cost effectiveness and implications for safety of assessing anti-tumour necrosis factor (TNF)α drug levels and antibodies in children with moderate to severe inflammatory bowel disease (IBD) compared with existing clinical strategies in use in NHSScotland? : in response to an enquiry from NHS Greater Glasgow and Clyde.
Healthcare Improvement Scotland.
Includes bibliographical references (pages 6-7)
System requirements: Adobe Reader required to view PDF document.
Description from online resource; title from PDF caption (Healthcare Improvement Scotland, viewed 5 February 2020)
Gastrointestinal system
Pediatric gastroenterology
Tumor necrosis factor